We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SKIKON.CO

Price
959.70
Stock movement up
+14.80 (1.57%)
Company name
SKAGEN Kon-Tiki A
Exchange
(CO
,
Currency
DKK
)
Markedsverdi
-
Ent verdi
-
Pris/omsetning
-
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
19.29%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2025-11-25

UTBYTTE

SKIKON.CO betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok-
EV i forhold til salg-

ØKONOMI

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning961.90
Daglig høy961.90
Daglig lav955.50
Daglig volum1K
Tidenes høyeste1070.92
1 år analytikerestimat-
Beta1.01
EPS (TTM)-
Utbytte per aksje0.00
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
SKIKON.COS&P500
Nåværende prisfall fra toppnotering-10.39%-1.80%
Høyeste prisfall-36.06%-19.00%
Dato for høyeste fall10 Apr 20258 Apr 2025
Gj.snittlig fall fra topp-22.23%-2.73%
Gj.snittlig tid til ny topp-6 days
Maks tid til ny topp276 days89 days
SELSKAPSOPPLYSNINGER
SKIKON.CO (SKAGEN Kon-Tiki A) company logo
Markedsverdi
-
Markedsverdi kategori
Small-cap
Beskrivelse
SKAGEN - Kon-Tiki fund is an open-ended equity mutual fund launched and managed by Skagen AS. The fund invests in public equity markets of emerging countries across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund invests in stocks of companies across diversified market capitalizations. It invests in value stocks of companies. It benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. SKAGEN - Kon-Tiki fund was formed on April 5, 2002 and is domiciled in Norway.
Ansatte
0
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Denmark
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Lysaker, 30 October 2025 Effective from 30 October 2025, SKAGEN AS will be merged into Storebrand Asset Management (Storebrand AM), but despite the structural changes, the same SKAGEN investment team ...
30. oktober 2025
Lysaker, 28 October 2025 The suspension is lifted for the below funds, and the live trading on Nasdaq Copenhagen can resume. Regards Storebrand Asset Management AS Contacts: Henrik Budde Gantzel, Dire...
28. oktober 2025
Lysaker, 28 October 2025 The below funds are suspended from the live trading on Nasdaq Copenhagen due to technical issues which affect NAV calculations, and hence, challenges to provide intrinsic valu...
28. oktober 2025
Lysaker, 27 October 2025 This is a re-submission of the announcement posted at 14:46, with reference to the correct fund (SKAGEN Focus A) at the bottom of this text. With reference to Nasdaq Copenhage...
27. oktober 2025
Lysaker, 27 October 2025 With reference to Nasdaq Copenhagen's rules for issuers of UCITS units, we hereby notify that incorrect intrinsic values were reported on 24 October for SKAGEN Focus A as deta...
27. oktober 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
9. september 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
9. september 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
9. september 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
9. september 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
9. september 2025
Neste side